Compile Data Set for Download or QSAR
Report error Found 329 Enz. Inhib. hit(s) with all data for entry = 9091
TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440840(US10639284, Compound 3.009 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440706(US10639284, Compound 3.008 | US10639284, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440842(US10639284, Compound 3.011 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440841(US10639284, Compound 3.010 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440836(US10639284, Compound 3.005 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440835(US10639284, Compound 3.004 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440838(US10639284, Compound 3.007 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440837(US10639284, Compound 3.006 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440832(US10639284, Compound 3.001 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440834(US10639284, Compound 3.003 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440833(US10639284, Compound 3.002 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440829(US10639284, Compound 2.176 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440856(US10639284, Compound 3.025 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440652(US10639284, Compound 3.024 | US10639284, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440858(US10639284, Compound 3.027 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440857(US10639284, Compound 3.026 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440852(US10639284, Compound 3.041 | US10639284, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440851(US10639284, Compound 3.020 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440853(US10639284, Compound 3.022 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440848(US10639284, Compound 3.017 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440847(US10639284, Compound 3.016 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440850(US10639284, Compound 3.019 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440849(US10639284, Compound 3.018 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440846(US10639284, Compound 3.015 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440852(US10639284, Compound 3.041 | US10639284, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440871(US10639284, Compound 3.040 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440874(US10639284, Compound 3.043 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440868(US10639284, Compound 3.037 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440870(US10639284, Compound 3.039 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440869(US10639284, Compound 3.071 | US10639284, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440864(US10639284, Compound 3.033 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440863(US10639284, Compound 3.032 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440865(US10639284, Compound 3.034 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440888(US10639284, Compound 3.057 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440890(US10639284, Compound 3.059 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440884(US10639284, Compound 3.053 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440885(US10639284, Compound 3.054 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440880(US10639284, Compound 3.049 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440879(US10639284, Compound 3.048 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440875(US10639284, Compound 3.044 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440878(US10639284, Compound 3.047 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440641(US10639284, Compound 1.009 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440903(US10639284, Compound 3.072 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440905(US10639284, Compound 3.074 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440900(US10639284, Compound 3.069 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440637(US10639284, Compound 1.005 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440899(US10639284, Compound 3.068 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440640(US10639284, Compound 1.008 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440869(US10639284, Compound 3.071 | US10639284, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM440901(US10639284, Compound 3.070 | US11426364, Compound ...)
Affinity DataIC50: 100nMAssay Description:Plates were coated with 1 g/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4 ° C. The wells were then blocked with PBS containing 2% BSA i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2021
Entry Details
US Patent

Displayed 1 to 50 (of 329 total ) | Next | Last >>
Jump to: